Share This Page
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Delflex W/ Dextrose 1.5% In Plastic Container, and when can generic versions of Delflex W/ Dextrose 1.5% In Plastic Container launch?
Delflex W/ Dextrose 1.5% In Plastic Container is a drug marketed by Fresenius Medcl and is included in three NDAs.
The generic ingredient in DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER is calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER?
- What are the global sales for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER?
- What is Average Wholesale Price for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER?
Summary for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 2 |
| DailyMed Link: | DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER at DailyMed |
Pharmacology for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
US Patents and Regulatory Information for DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
DELFLEX W/ DEXTROSE 1.5% in Plastic Container: Market Dynamics, Patent Position, and Financial Trajectory
DELFLEX with Dextrose 1.5% is a low-strength peritoneal dialysis solution used for intraperitoneal fluid exchange in patients with end-stage renal disease. The product is a mature, sterile dialysis consumable rather than a patent-driven pharmaceutical. Its commercial outlook depends primarily on peritoneal dialysis utilization, Medicare reimbursement, manufacturing capacity, hospital and dialysis-provider contracts, and the competitive positions of Fresenius Medical Care and Baxter.
Product-level revenue is not publicly reported. The financial trajectory is therefore best assessed through the peritoneal dialysis market, the manufacturer’s dialysis business, U.S. reimbursement policy, and the product’s regulatory and competitive characteristics.
What is DELFLEX with Dextrose 1.5%?
DELFLEX with Dextrose 1.5% is a peritoneal dialysis solution containing dextrose at a concentration of 1.5%. It is supplied in a plastic container for intraperitoneal administration.
| Attribute | Product information |
|---|---|
| Product | DELFLEX with Dextrose 1.5% |
| Therapeutic category | Peritoneal dialysis solution |
| Active osmotic agent | Dextrose |
| Concentration | 1.5% |
| Dosage form | Sterile dialysis solution |
| Route | Intraperitoneal |
| Primary use | Continuous ambulatory and automated peritoneal dialysis |
| U.S. regulatory status | Prescription medical product |
| Product type | Chemical dialysis fluid, not a biologic |
| Principal commercial issue | Volume demand and supply reliability |
| Product-level revenue disclosure | Not separately reported |
The 1.5% concentration is generally used when a relatively lower osmotic gradient is appropriate. Higher dextrose concentrations, including 2.5% and 4.25%, remove more fluid but carry greater risks of glucose absorption and metabolic complications. The choice of concentration depends on the patient’s fluid status and dialysis prescription. The product label identifies peritoneal dialysis solution as the treatment modality and includes warnings relating to infection, electrolyte abnormalities, hyperglycemia, and fluid imbalance.[1]
Who manufactures and markets DELFLEX?
DELFLEX is associated with Fresenius Medical Care North America. Fresenius Medical Care is a vertically integrated renal-care company with dialysis clinics, products, services, and home-dialysis capabilities. The company sells dialysis solutions and related consumables through institutional, clinic, and home-dialysis channels.
The key commercial implication is that DELFLEX competes within an integrated dialysis ecosystem. Purchasing decisions may be influenced by:
- Clinic formularies and dialysis-provider contracts.
- Compatibility with automated peritoneal dialysis systems.
- Home-dialysis training and supply logistics.
- Contract pricing with large provider networks.
- Product availability and continuity of supply.
- Switching costs associated with established patient protocols.
Baxter is the principal global competitor in peritoneal dialysis solutions and automated peritoneal dialysis equipment. Fresenius and Baxter therefore compete at the platform level, not only on the price of an individual dialysis bag.
How large is the peritoneal dialysis market?
Peritoneal dialysis represents a minority of global dialysis treatments but has strategic value because it can be delivered at home and generally requires less clinic infrastructure than hemodialysis. Growth is supported by:
- Increasing prevalence of chronic kidney disease and end-stage renal disease.
- Government policies favoring home dialysis.
- Provider efforts to reduce in-center treatment costs.
- Patient demand for home-based care.
- Expansion of dialysis capacity in emerging markets.
The United States has promoted home dialysis through the Advancing American Kidney Health initiative and subsequent payment reforms. The policy framework set a long-term objective of increasing home dialysis and kidney transplantation, although actual adoption depends on patient suitability, training capacity, caregiver support, housing conditions, and provider economics.[2]
Peritoneal dialysis remains operationally sensitive to supply availability. Each patient can require repeated daily exchanges, producing recurring demand for solution bags, transfer sets, tubing, and related consumables. This recurring-use model makes utilization more important than one-time prescription volume.
What is the financial trajectory for DELFLEX?
DELFLEX’s product-level financial trajectory is likely stable to moderately growing, with limited pricing power. The main drivers are patient census, treatment modality mix, reimbursement, manufacturing costs, and supply contracts.
| Financial driver | Expected effect on DELFLEX |
|---|---|
| Growth in peritoneal dialysis patients | Positive volume effect |
| Shift from hemodialysis to home dialysis | Positive |
| Medicare bundled reimbursement | Limits stand-alone price increases |
| Dextrose and packaging costs | Margin pressure |
| Sterile manufacturing capacity | Can constrain sales and raise costs |
| Provider consolidation | Increases contract pricing pressure |
| Home-dialysis adoption | Positive long-term demand |
| Product substitution among dialysis solutions | Moderate competitive risk |
| Patent expiration | Limited direct effect because the product is mature |
| Supply interruptions | Potentially material short-term revenue impact |
The product is a recurring consumable. Revenue should therefore track treated patient-months and supply volumes rather than conventional pharmaceutical launch curves. A reasonable commercial pattern is:
- Mature baseline demand.
- Low single-digit volume growth where home dialysis expands.
- Periodic revenue volatility from shortages, plant outages, contract changes, or reimbursement revisions.
- Limited contribution from price increases because dialysis providers operate under reimbursement and budget constraints.
Fresenius Medical Care reports at the segment level and does not generally disclose sales for individual dialysis solutions such as DELFLEX. The product’s financial contribution is therefore embedded within broader dialysis product or care-delivery revenues.[3]
How does U.S. reimbursement affect DELFLEX demand?
U.S. dialysis reimbursement is a central market variable. Under the Medicare End-Stage Renal Disease Prospective Payment System, many dialysis-related items and services are paid through a bundled payment. The bundle creates an incentive for providers to manage total treatment cost, including dialysis solutions and ancillary supplies.[4]
For DELFLEX, bundled reimbursement has several effects:
- It makes dialysis providers sensitive to unit cost.
- It favors reliable products that reduce clinical and logistical disruption.
- It limits the ability to pass through manufacturing cost increases.
- It can encourage providers to standardize on a preferred supplier.
- It increases the importance of supply-chain performance.
Commercial insurers and integrated dialysis providers may use purchasing scale to negotiate discounts. A manufacturer with a broad dialysis portfolio can offset pressure on individual product margins through equipment, services, and clinic relationships.
What patents protect DELFLEX with Dextrose 1.5%?
DELFLEX with Dextrose 1.5% does not appear to rely on a meaningful current patent monopoly. It is a mature aqueous dialysis solution containing dextrose, electrolytes, and buffer components in a plastic container.
The primary competitive barriers are operational rather than patent-based:
- Sterile compounding and filling.
- Validated container-closure systems.
- Quality-control testing.
- Manufacturing scale.
- Drug-supply-chain qualification.
- Clinic and home-delivery logistics.
- Regulatory compliance.
- Product compatibility and customer conversion costs.
The U.S. FDA Orange Book generally lists approved drug products with patents and regulatory exclusivity information, but mature dialysis solutions may have limited or no relevant listed-patent protection. No commercially material Orange Book patent estate is associated with DELFLEX with Dextrose 1.5% in the public product information reviewed for this analysis.[5]
Are there formulation patents for DELFLEX?
A specific patent position could theoretically cover a formulation, container, manufacturing process, or dialysis-system interface. Such patents would not necessarily appear as a strong Orange Book barrier, particularly if they are expired, not listed, or unrelated to the marketed concentration.
For the 1.5% product, the formulation itself is unlikely to support durable premium pricing because:
- Dextrose-based peritoneal dialysis solutions are established technology.
- Multiple suppliers market comparable dextrose concentrations.
- The composition is relatively standardized.
- Clinicians can often substitute among equivalent products subject to compatibility and contractual constraints.
The commercial value of any remaining intellectual property would therefore be narrower than the value of the manufacturing network and customer base.
When does DELFLEX lose exclusivity?
DELFLEX is a mature product and does not have a conventional near-term patent-cliff profile comparable to a branded small-molecule drug. The relevant exclusivity has already expired or is not commercially decisive.
| Exclusivity category | Assessment |
|---|---|
| New chemical entity exclusivity | Not commercially relevant |
| Biologic exclusivity | Not applicable |
| Orphan-drug exclusivity | Not applicable |
| Formulation exclusivity | No material current barrier identified |
| Orange Book patent exclusivity | No material current barrier identified |
| Manufacturing know-how | Potentially important but not statutory exclusivity |
| Customer and supply contracts | Commercial barrier, not patent exclusivity |
Generic or alternative-source entry is possible in principle, but a competitor must meet FDA requirements for sterile production, product quality, labeling, packaging, and supply reliability. The practical entry barrier is higher than the legal exclusivity profile suggests.
Which companies compete with DELFLEX?
Baxter
Baxter is the most direct competitor because it has a large peritoneal dialysis franchise, including dialysis solutions, automated peritoneal dialysis systems, and home-care infrastructure. Its scale creates a strong installed-base advantage.
Fresenius Medical Care
Fresenius competes through dialysis clinics, home-dialysis programs, equipment, solutions, and services. This integration can support product adoption within its own network and strengthen supply-contract positioning.
Regional and local suppliers
Other manufacturers may compete in selected countries or institutional accounts. Their ability to displace a major supplier is constrained by:
- Regulatory approvals.
- Sterile manufacturing capacity.
- Distribution requirements.
- Patient transition procedures.
- Provider qualification.
- Long-term supply commitments.
Competition is therefore concentrated among suppliers with validated facilities and established dialysis distribution.
What generic entry risks exist for DELFLEX?
The generic entry risk is moderate in legal terms and low to moderate in practical terms.
A new entrant would not face a major active-molecule patent barrier. It would face execution risks involving:
- Aseptic or terminal-sterilization validation.
- Container integrity.
- Stability data.
- Electrolyte and glucose concentration control.
- Large-volume production.
- Shortage management.
- FDA inspection readiness.
- Distribution to clinics and patients.
- Contract conversion.
A new supplier could compete through lower pricing, but price alone may not overcome concerns about supply continuity. Dialysis providers have strong incentives to avoid shortages because interruption of peritoneal dialysis treatment can create immediate clinical risk.
Are there Paragraph IV challenges or patent lawsuits?
No material Paragraph IV challenge or product-specific patent litigation affecting DELFLEX with Dextrose 1.5% is identified in the public product record reviewed for this analysis.
That result is consistent with the product’s commercial profile. Paragraph IV litigation is more common for branded drugs with active Orange Book patents and substantial expected generic revenue. A mature dialysis solution with limited listed patent protection is more likely to face regulatory competition, contract competition, or supply-based substitution than a high-value patent challenge.
Litigation risk may still arise from:
- Product liability.
- Manufacturing defects.
- Contamination.
- Labeling.
- Supply contracts.
- Antitrust issues involving dialysis networks.
- Intellectual property relating to dialysis equipment or packaging.
Those risks are distinct from a DELFLEX-specific patent cliff.
What is the FDA regulatory status of DELFLEX?
DELFLEX is regulated as a prescription dialysis solution. The FDA-approved labeling addresses peritoneal administration, patient selection, dosing considerations, warnings, precautions, adverse reactions, and storage and handling requirements.[1]
The principal regulatory risks are manufacturing and quality risks rather than clinical-development risks. Relevant compliance areas include:
- Sterility assurance.
- Endotoxin control.
- Container-closure integrity.
- Correct concentration and electrolyte composition.
- Label accuracy.
- Stability through shelf life.
- Good manufacturing practice compliance.
- Complaint handling and adverse-event reporting.
Because the product is used repeatedly and often in the home, labeling clarity and supply reliability are commercially important.
What is the Orange Book status of DELFLEX?
DELFLEX is not positioned as a patent-protected branded drug with a significant Orange Book exclusivity runway. The principal commercial protection comes from manufacturing qualification, distribution, provider relationships, and regulatory execution.
The Orange Book should be checked for the specific active listing, NDC, application number, and any patent certifications at the time of a transaction or litigation assessment. Public product information does not indicate a current, material patent barrier that would prevent alternative manufacturers from seeking approval.[5]
What manufacturing and intellectual-property barriers affect the product?
The strongest barriers are technical and operational.
Sterile manufacturing
Peritoneal dialysis solutions are large-volume sterile products. Production requires validated mixing, filling, sterilization, packaging, and testing systems. A failure at one plant can affect a large patient population.
Packaging
The plastic container is part of the product’s delivery and stability profile. It must maintain solution quality, prevent leakage, support handling, and preserve container integrity throughout distribution and use.
Distribution
The home-dialysis model requires regular delivery of bulky, heavy supplies. Freight, warehousing, and last-mile distribution can materially affect margins. Local shortages can create rapid customer-switching pressure.
Manufacturing know-how
Process controls and quality systems may be protected through trade secrets and regulatory know-how rather than enforceable product patents. This protection is durable only while the manufacturer maintains reliable execution.
How does DELFLEX compare with Baxter peritoneal dialysis solutions?
| Factor | DELFLEX | Baxter peritoneal dialysis solutions |
|---|---|---|
| Core product | Dextrose-based PD solution | Broad PD solution portfolio |
| Concentration | 1.5% dextrose product | Multiple concentrations and formulations |
| Market position | Integrated Fresenius ecosystem | Large global PD installed base |
| Patent dependence | Low | Low to moderate, depending on formulation or system |
| Main barrier | Manufacturing and supply reliability | Manufacturing, equipment, and installed base |
| Revenue disclosure | Not product-specific | Not product-specific |
| Competitive strength | Provider integration | Scale and broad home-dialysis platform |
| Primary risk | Contract loss or supply disruption | Regulatory, manufacturing, and portfolio execution |
DELFLEX’s competitive position is strongest where Fresenius controls the dialysis-provider relationship or can offer a coordinated equipment-and-solution package. Baxter’s advantage is its scale and established global presence in peritoneal dialysis.
What is the outlook for revenue and margins?
The base case is a mature, recurring-revenue product with modest volume growth and constrained pricing.
Base case
Peritoneal dialysis utilization grows gradually, supporting stable DELFLEX demand. Margin remains under pressure from labor, energy, plastics, transportation, and quality-control costs.
Upside case
Home-dialysis adoption expands faster than expected, reimbursement favors peritoneal dialysis, and supply reliability improves. DELFLEX benefits from higher patient volumes and stronger utilization within the Fresenius network.
Downside case
Baxter or another supplier wins contracts, a manufacturing disruption creates shortages, or reimbursement pressure increases. Volume declines can be amplified because dialysis providers may standardize on a competing supplier across clinics.
The most important financial metric is not the price of a single bag. It is the number of active peritoneal dialysis patients supplied over time and the manufacturer’s share of their recurring solution demand.
Key Takeaways
- DELFLEX with Dextrose 1.5% is a mature peritoneal dialysis solution associated with Fresenius Medical Care.
- Product-level revenue and margin are not publicly disclosed.
- The commercial outlook is tied to peritoneal dialysis patient growth, home-dialysis adoption, reimbursement, and supply reliability.
- The product does not appear to have a material current Orange Book patent moat.
- Generic entry is legally feasible but operationally difficult because of sterile manufacturing, packaging, quality, and distribution requirements.
- Baxter is the principal direct competitor.
- The most material risks are contract displacement, manufacturing interruption, regulatory quality events, and reimbursement pressure.
- Financial performance should be modeled through patient-month volumes, supplier share, average realized price, manufacturing cost, and logistics cost rather than through a conventional patent-expiry forecast.
FAQs
Is DELFLEX 1.5% a generic drug?
DELFLEX is a mature prescription dialysis solution, but its competitive status is better understood as a sterile medical product competing on manufacturing, supply, and contracts rather than as a conventional small-molecule generic.
Can patients switch from DELFLEX to Baxter dialysis solution?
A switch may be clinically possible in some cases, but it requires confirmation of formulation, concentration, equipment compatibility, prescription requirements, and patient-specific dialysis management.
Does DELFLEX have biosimilar competition?
No. DELFLEX is not a biologic and is not subject to the FDA biosimilar pathway.
What would make DELFLEX revenue grow?
The strongest growth drivers are increased peritoneal dialysis adoption, expansion of home dialysis, higher Fresenius patient volumes, and successful retention of provider supply contracts.
Is DELFLEX exposed to a major patent cliff?
No material conventional patent cliff is apparent. Its principal exposure is commercial and operational: competitive contracts, supply reliability, regulatory compliance, and production economics.
References
-
U.S. National Library of Medicine. (n.d.). DELFLEX with 1.5% dextrose peritoneal dialysis solution: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Department of Health and Human Services. (2019). Advancing American kidney health. https://aspe.hhs.gov/
-
Fresenius Medical Care AG & Co. KGaA. (2024). Annual report 2023. https://annualreport.freseniusmedicalcare.com/
-
Centers for Medicare & Medicaid Services. (2024). End-stage renal disease prospective payment system. https://www.cms.gov/medicare/payment/prospective-payment-systems/end-stage-renal-disease-esrd
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
More… ↓
